Pharmacokinetic Study of Mizoribine Child-onset Renal Diseases

Abstract

The pharmacokinetic study of mizoribine was conducted in 6 cases of child-onset renal diseases with normal renal function. The profile of the serum and urinary concentrations of mizoribine was determined. Mizoribine at daily dose of 60 mg to 250 mg (3.6∼5.0 mg/kg/day) was orally given divided into two doses. Pharmacokinetic parameters for mizoribine estimated by concentration-time profiles. Obtained pharmacokinetic values were : Tmax 2.78±0.95 hours, mean peak blood level (Cmax) of mizoribine 0.67±0.16μg/ml, T 1/2 2.12±0.51 hours, AUC 3.76±1.15μg · h/ml, cumulative urinary excretion 38.6±9.6%.
parameters obtained in the present study seemed to be useful for mizoribine treatment of patients with child-onset renal diseases.